Celgene Corporation (CELG) Position Maintained by USS Investment Management Ltd

USS Investment Management Ltd continued to hold its stake in Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 927,000 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Celgene Corporation accounts for 1.1% of USS Investment Management Ltd’s investment portfolio, making the stock its 21st largest position. USS Investment Management Ltd owned approximately 0.12% of Celgene Corporation worth $120,389,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of CELG. Waldron LP boosted its holdings in Celgene Corporation by 48.9% in the 1st quarter. Waldron LP now owns 5,207 shares of the biopharmaceutical company’s stock worth $640,000 after acquiring an additional 1,709 shares during the period. Girard Partners LTD. boosted its holdings in Celgene Corporation by 19.0% in the 1st quarter. Girard Partners LTD. now owns 12,909 shares of the biopharmaceutical company’s stock worth $1,606,000 after acquiring an additional 2,061 shares during the period. Boston Partners boosted its holdings in Celgene Corporation by 0.3% in the 1st quarter. Boston Partners now owns 197,861 shares of the biopharmaceutical company’s stock worth $24,620,000 after acquiring an additional 541 shares during the period. HPM Partners LLC boosted its holdings in Celgene Corporation by 297.1% in the 1st quarter. HPM Partners LLC now owns 69,504 shares of the biopharmaceutical company’s stock worth $8,648,000 after acquiring an additional 51,999 shares during the period. Finally, Checchi Capital Advisers LLC boosted its holdings in Celgene Corporation by 8.0% in the 1st quarter. Checchi Capital Advisers LLC now owns 8,141 shares of the biopharmaceutical company’s stock worth $1,013,000 after acquiring an additional 603 shares during the period. Institutional investors and hedge funds own 79.39% of the company’s stock.

WARNING: “Celgene Corporation (CELG) Position Maintained by USS Investment Management Ltd” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.com-unik.info/2017/10/31/celgene-corporation-celg-position-maintained-by-uss-investment-management-ltd.html.

A number of research firms have weighed in on CELG. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $166.00 price target (up previously from $163.00) on shares of Celgene Corporation in a report on Monday. Cantor Fitzgerald restated a “hold” rating and issued a $112.00 price target on shares of Celgene Corporation in a report on Monday. J P Morgan Chase & Co set a $123.00 price target on Celgene Corporation and gave the stock a “buy” rating in a report on Friday. UBS AG decreased their price target on Celgene Corporation from $146.00 to $120.00 and set a “buy” rating for the company in a report on Friday. Finally, Canaccord Genuity restated a “buy” rating and issued a $140.00 price target (down previously from $154.00) on shares of Celgene Corporation in a report on Friday. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $139.64.

In other Celgene Corporation news, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total value of $1,008,900.00. Following the completion of the transaction, the director now owns 76,301 shares in the company, valued at approximately $10,264,010.52. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the transaction, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 46,233 shares of company stock valued at $6,268,259. Corporate insiders own 0.95% of the company’s stock.

Celgene Corporation (NASDAQ CELG) opened at 100.97 on Tuesday. Celgene Corporation has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a market cap of $78.99 billion, a PE ratio of 31.27 and a beta of 1.89. The stock has a 50 day moving average price of $135.78 and a 200 day moving average price of $129.85.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the previous year, the company posted $1.58 EPS. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. Equities analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current year.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit